TBR-760

Tiburio is developing TBR-760, a dopamine-somatostatin chimeric compound, for the treatment of non-functioning pituitary adenoma, or NFPA.

Tiburio is developing TBR-760, a dopamine-somatostatin chimeric compound, for the treatment of non-functioning pituitary adenoma, or NFPA.

Tiburio’s TBR-760 is a potential breakthrough in the treatment of non-functioning pituitary adenoma (NFPA). TBR-760, a dopamine-somatostatin chimeric compound, is designed to inhibit NFPA cell proliferation with the potential to shrink or halt tumor growth.

Tiburio expects to move TBR-760 into a Phase 2 clinical trial in patients with NFPA in the second half of 2019.

TBR-760 is a member of a unique class of chimeric compounds that combine structural elements of both dopamine and somatostatin, and that retain the ability to bind and activate both dopamine and somatostatin receptors.  Studies suggest that these chimeric compounds may facilitate physical interactions between dopamine and somatostatin receptors that results in enhanced activity.

PreclinicalPhase 1Phase 2Phase 3
Preclinical
Phase 1
Phase 2
Phase 3